Form 4: Agios Pharmaceuticals CEO Brian Goff Reports Stock Transactions Following Performance Share Unit Vesting

Agios Pharmaceuticals CEO Brian Goff reported the acquisition of common stock through performance share unit vesting and subsequent sales to cover tax obligations, executed under pre-arranged Rule 10b5-1 plans.

Summary

• Brian Goff, Chief Executive Officer and Director of Agios Pharmaceuticals, Inc. (AGIO), reported multiple transactions involving the company's common stock on June 24, 2025.
• He acquired 25,527 shares of common stock at a price of $0 through the vesting of performance share units (PSUs) granted on August 8, 2022.
• Following this acquisition, he disposed of 12,471 shares of common stock at a price of $33.54 per share to cover tax withholding obligations related to the PSU vesting.
• Additionally, he acquired 12,750 shares of common stock at a price of $0 through the vesting of PSUs granted on March 1, 2023.
• Subsequently, he disposed of 6,229 shares of common stock at a price of $33.54 per share, also to cover tax withholding obligations for the second PSU vesting.
• All sales were conducted pursuant to durable automatic sale instructions consistent with Rule 10b5-1(c) plans.
• The vesting of the August 8, 2022 PSUs (15% of underlying shares) was triggered by the achievement of a specified research milestone on June 24, 2025.
• The vesting of the March 1, 2023 PSUs (50% of underlying shares) was also triggered by the achievement of a specified research milestone on June 24, 2025.
• After these transactions, Brian Goff's direct beneficial ownership of common stock was 111,922 shares, and he held 51,056 and 12,750 performance share units respectively from the two grants.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While there are sales of shares, they are for tax purposes and pre-planned, which is neutral. The underlying reason for the transactions, the vesting of performance share units due to the achievement of research milestones, is a positive indicator of company progress.

Positives

• The vesting of performance share units indicates the successful achievement of specified research milestones by Agios Pharmaceuticals, which is a positive operational indicator.
• The transactions were executed under Rule 10b5-1 plans, demonstrating pre-planned and transparent insider trading activity.

Negatives

• The disposition of 12,471 shares and 6,229 shares, totaling 18,700 shares, reduces the CEO's direct ownership in the company, although these sales were for tax withholding purposes.

Risks

• The document does not explicitly mention risks beyond the inherent nature of stock-based compensation and tax obligations.

Future Outlook

The document indicates that remaining performance share units from the August 8, 2022 grant will vest upon the achievement of other clinical and regulatory milestones. Similarly, the remaining 50% of the March 1, 2023 PSUs will vest upon the achievement of a specified regulatory milestone. Vested shares will be delivered within three business days after vesting.

Management Comments

• The transactions were effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's performance share unit agreements.

Industry Context

This Form 4 filing details routine insider transactions related to executive compensation, specifically the vesting of performance-based equity awards and subsequent 'sell-to-cover' tax sales. Such transactions are common across the biotechnology and pharmaceutical industries as a standard component of executive compensation packages, aligning management incentives with company performance and shareholder value.

Comparison to Industry Standards

• The use of performance share units (PSUs) tied to specific research, clinical, and regulatory milestones is a common practice in the biotechnology and pharmaceutical sectors, aligning executive compensation with R&D progress and product development success.
• The 'sell-to-cover' mechanism for tax withholding is a standard and widely accepted practice for equity compensation across all industries, including biotech, to manage the tax implications of vested shares.
• The execution of these transactions under Rule 10b5-1 plans is a best practice for corporate governance, providing transparency and mitigating concerns about opportunistic insider trading, consistent with practices at comparable companies like Vertex Pharmaceuticals or Biogen, which also utilize similar equity compensation structures and 10b5-1 plans for their executives.

Corporate Governance

Stakeholder Impact

• Shareholders: The report provides transparency into the CEO's equity compensation and ownership changes. The vesting of PSUs indicates progress on company milestones, which could be viewed positively.
• Employees: The achievement of research milestones leading to PSU vesting may signal positive progress within the company's R&D efforts.

Next Steps

• Vested shares will be delivered to the reporting person within three business days after such shares become vested.
• Remaining performance share units from the August 8, 2022 grant are subject to vesting upon achievement of other clinical and regulatory milestones.
• The remaining 50% of performance share units from the March 1, 2023 grant are subject to vesting upon achievement of a specified regulatory milestone.

Key Dates

Keywords

Agios Pharmaceuticals, AGIO, Brian Goff, CEO, Director, SEC Form 4, Insider Trading, Performance Share Units, PSUs, Stock Vesting, Rule 10b5-1, Tax Withholding, Equity Compensation